Analysts have been eager to weigh in on the Healthcare sector with new ratings on NovoCure (NVCR – Research Report), Insmed (INSM – Research Report) and Bristol-Myers Squibb (BMY – Research Report).
NovoCure (NVCR)
In a report issued on October 26, Jonathan Chang from Leerink Partners reiterated a Buy rating on NovoCure, with a price target of $38.00. The company’s shares closed last Monday at $13.06, close to its 52-week low of $12.37.
According to TipRanks.com, Chang ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
NovoCure has an analyst consensus of Strong Buy, with a price target consensus of $39.25, representing a 207.4% upside. In a report issued on October 26, Wells Fargo also maintained a Buy rating on the stock with a $49.00 price target.
See today’s best-performing stocks on TipRanks >>
Insmed (INSM)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Insmed on October 26 and set a price target of $50.00. The company’s shares closed last Monday at $23.80.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Insmed is a Strong Buy with an average price target of $43.45, representing an 80.7% upside. In a report issued on October 26, TD Cowen also maintained a Buy rating on the stock with a $45.00 price target.
Bristol-Myers Squibb (BMY)
Leerink Partners analyst David Risinger maintained a Hold rating on Bristol-Myers Squibb on October 26 and set a price target of $53.00. The company’s shares closed last Monday at $51.25, close to its 52-week low of $49.49.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Bristol-Myers Squibb has an analyst consensus of Moderate Buy, with a price target consensus of $62.92, which is a 21.6% upside from current levels. In a report issued on October 20, UBS also initiated coverage with a Hold rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NVCR:
- Novocure reports Q3 EPS (46c), consensus (52c)
- Novocure teams with Stanford to create TTFields research program
- Novocure announces data from the randomized phase 3 LUNAR clinical trial
- Novocure price target lowered to $49 from $102 at Wells Fargo
- Novocure downgraded to Neutral after study failure at H.C. Wainwright
